MyringoPatch™

What is MyringoPatch?

Freeze-Dried Fascia Lata Graft

MyringoPatch™ is a sterile, freeze-dried human fascia lata allograft designed for ENT surgery. Its collagen-rich architecture provides a biologically compatible scaffold for tissue healing and structural repair—without the need to harvest autologous fascia.

Trusted Biological Repair for Tympanic Membrane, Nasal, and Mastoid Reconstruction

Clinical Applications

Tympanic Membrane Repair (Myringoplasty/ Tympanoplasty)

- Studies suggest closure rates of 87–90%, similar to autologous fascia
- Maintains shape and tensile integrity for durable closure
- Supports large, anterior, and subtotal perforations
- Effective in both primary and revision procedures
- Eliminates donor-site morbidity and reduces OR timeChronic Otitis Media / Mastoid Cavity Lining

Canal Wall Down Mastoidectomy (CWD)

- Used to line the mastoid cavity and middle ear space after debridement
- Clinical evidence suggests fascia lata supports epithelialization and reduces cavity granulation
- Ideal in revision or chronically infected cases
- Offers a non-autologous solution when native fascia is unavailable or compromised

Nasal Septal Repair (Septoplasty & Perforation Closure)

- Effective in perforations >2 cm, with closure success >88%
- Conforms to nasal contours and supports mucosal regeneration
- Preferred in revision cases and scarred septal beds
- May be layered with cartilage or fat for enhanced reconstruction

Skull Base & Other ENT Uses

- Applied in endoscopic skull base repair with CSF leak closure rates ~88–92%
- Comparable to autograft and acellular dermal matrix in duraplasty
- Can be used to reinforce nasal wall, orbital floor, or cranial base defects

Clinical Highlights

- Human-derived collagen scaffold
- Strong, flexible, and easy to handle
- No autograft harvest required
- Resists degradation in moist or contaminated environments
- Shelf-stable, rehydrates quickly in saline
- FDA 21 CFR 1271 HCT/P compliant
- Backed by 20+ years of peer-reviewed clinical use in ENT and neuro applications

Ordering Information

Code	Description	Size	Thickness
BE1010FD	MyringoPatch - M	10 MM	0.2 MM
BE1016FD	MyringoPatch - L	16 MM	0.2 MM
BE1030FD	MyringoPatch - XL	25 x 30 MM	0.2 MM

BioMed ENT is ISO 13485 certified, underscoring a commitment to maintaining high standards in medical device manufacturing. In partnership with leading universities and hospitals, BioMed ENT is also working toward achieving ISO 14001 certification by 2027 to reinforce environmental sustainability.

Regulatory Disclaimer

MyringoPatch™ is regulated as a human cell, tissue, and cellular and tissue-based product (HCT/P) under FDA 21 CFR Part 1271. It is intended for homologous use only. This product is not intended to diagnose, treat, cure, or prevent any disease. All statements referencing clinical outcomes are derived from peer-reviewed studies evaluating the use of fascia lata in ENT procedures. Surgeon judgment should guide all clinical applications.